Journal: Oncotarget

Article Title: Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids

doi: 10.18632/oncotarget.28134

Figure Lengend Snippet: At day 3 post-seeding, H2052/484 spheroids (1000 cells/spheroid) were treated for 3 hours with different concentrations of cisplatin (50, 100, or 200 μM) ( A , B ) or cisplatin/pemetrexed combination (50/200, 100/400, or 200/800 μM) ( C , D ). After washes, the spheroids were cultured for 17 days, the growth (A, C) and the ATPi kinetics (B, D) were assessed. The data represent the mean ± SD of 3 independent experiments. * P < 0.05; ** P < 0.01 comparing treated groups with control group.

Article Snippet: Pemetrexed (Tocris Bioscience, Bristol, UK) was dissolved in sterile DMSO (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) at concentrations of 10 mg/ml.

Techniques: Cell Culture, Control

Journal: PLoS ONE

Article Title: Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

doi: 10.1371/journal.pone.0139809

Figure Lengend Snippet: (A): A549 cells were treated with or without 1 to 10nM of Gemcitabine (GEM), Pemetrexed (PEM), Docetaxel (DTX) or Vinorelbine (VNR) for 24 hours, then the expression of MHC class I molecules and NKG2D ligands were assessed by flow cytometry. (B): The relative MFI (rMFI) of MHC class I molecules and NKG2D ligands were calculated based on at least three independent experiments and evaluated with a Student t -test. Bars, SEM. * -p<0.05 and ** -p<0.01.

Article Snippet: Gemcitabine (Tocris Bioscience, #3259), Pemetrexed (Santa Cruz, #sc–219564), Vinorelbine (Santa Cruz, #sc–216059), Caffeine (Tocris Bioscience, #2793) and N-acetyl-L-cysteine (NAC) (Sigma-Aldrich, #A9165) were dissolved in PBS (-).

Techniques: Expressing, Flow Cytometry

Journal: Lung cancer (Amsterdam, Netherlands)

Article Title: Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.

doi: 10.1016/j.lungcan.2021.03.018

Figure Lengend Snippet: Fig. 4. Concentrations of soluble CRT in plasma of NSCLC patients before and after the onset of treatment with cytotoxic agents or osimertinib. (A) The plasma concentration of soluble CRT was determined before (pre), on days 3 and 8 of, and after the end of the first cycle of chemo therapy with DTX (n = 12) or PEM (n = 4) in patients with advanced NSCLC. The maximum (max) value for soluble CRT observed after the onset of treatment was then compared with the corresponding baseline value. **P < 0.01 (Wilcoxon matched-pairs signed-rank test). (B) The plasma concentration of soluble CRT was determined before (pre), on days 3 and 8 of, and about 1 month after the onset of osimertinib therapy in patients with EGFR-mutated advanced NSCLC (n = 9). The maximum (max) value for soluble CRT observed after the onset of treatment was then compared with the cor responding baseline value. ***P < 0.001 (Wil coxon matched-pairs signed-rank test).

Article Snippet: Pemetrexed disodium (PEM) was obtained from LKT Laboratories; docetaxel (DTX), cisplatin (CDDP), and carboplatin (CBDCA) were from Tocris; gemcitabine (GEM) was from Tronto; and paclitaxel (PTX), vinorelbine ditartrate (VNR), dimethyl sulfoxide were from Wako, and Z-VAD-FMK was from Selleck.

Techniques: Clinical Proteomics, Concentration Assay